GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway

Molecular Cancer Therapeutics

Volumn 10, Issue 12, 2011, Pages 2426-2436

  Wallin, Jeffrey J ^a   Edgar, Kyle A ^a   Guan, Jane ^a   Berry, Megan ^a   Prior, Wei Wei ^a   Lee, Leslie ^a   Lesnick, John D ^a   Lewis, Cristina ^a   Nonomiya, Jim ^a   Pang, Jodie ^a   Salphati, Laurent ^a   Olivero, Alan G ^a   Sutherlin, Daniel P ^a   O'Brien, Carol ^a   Spoerke, Jill M ^a   Patel, Sonal ^b   Lensun, Letitia ^b   Kassees, Robert ^a   Ross, Leanne ^a   Lackner, Mark R ^a   Sampath, Deepak ^a   Belvin, Marcia ^a   Friedman, Lori S ^a   more..

^a GENENTECH INC   (United States)

^b Piramed   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; DOCETAXEL; GDC 0980; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; HCT116 CELLS; HUMANS; MICE; MODELS, THEORETICAL; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83355163329     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0446     Document Type: Article

References (29)

1. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-510.
2. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004;9:667-76. (Pubitemid 40941196)
3. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005;5:921-9. (Pubitemid 41766781)
4. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/ AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
5. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010;16:4325-30.
6. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005;65:10992-1000. (Pubitemid 41713369)
7. Mukherjee A, Samanta S, Karmakar P. Inactivation of PTEN is responsible for the survival of Hep G2 cells in response to etoposide-induced damage. Mutat Res 2011;715:42-51.
8. Najmudin S, Pinheiro BA, Romao MJ, Prates JA, Fontes CM. Purification, crystallization and crystallographic analysis of Clostridium thermocellum endo-1,4-beta-D-xylanase 10B in complex with xylohexaose. Acta Crystallogr Sect F Struct Biol Cryst Commun 2008;64:715-8.
9. Opel D, Poremba C, Simon T, Debatin KM, Fulda S. Activation of Akt predicts poor outcomein neuroblastoma. Cancer Res 2007;67:735-45. (Pubitemid 46192214)
10. Razis E,Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 2011;128:447-56.
11. Tsang CK, Qi H, Liu LF, Zheng XF. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007;12:112-24. (Pubitemid 46176669)
12. Cybulski N, Hall MN. TOR complex 2: a signaling pathway of its own. Trends Biochem Sci 2009;34:620-7.
13. Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 2009;36(Suppl 3): S3-17.
14. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin- 1-ylmethyl)-4-morpholin -4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008;51: 5522-32.
15. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851-63.
16. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.
17. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009;15:4649-64.
18. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 2009;7:511-22.
19. Castanedo GD, Dotson J, Goldsmith R, Gunzner J, Heffron T, Mathieu S, et al. Inventor phosphoinositide 3-kinase inhibitor compounds and methods of use. 2008;WO2008/073785:A2.
20. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007;67:5840-50. (Pubitemid 46985018)
21. Zheng XF, Florentino D, Chen J, Crabtree GR, Schreiber SL. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 1995;82:121-30.
22. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 30 kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010;16:3670-83.
23. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004;145:5439-47. (Pubitemid 39564581)
24. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 1998;273: 33533-9. (Pubitemid 29005737)
25. Finlay M, inventor GLOBALINTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 S€odert€alje (SE), assignee. Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders. GB 2008;WO/ 2008/023159.
26. Wallin JJ, Guan J, Prior WW, Edgar KA, Kassees R, Sampath D, et al. Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer. Sci Transl Med 2010;2: 48ra66.
27. Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs 2005;65:2513-31. (Pubitemid 41697318)
28. Marsh S. Pharmacogenomics of taxane/platinum therapy in ovarian cancer. Int J Gynecol Cancer 2009;19(Suppl 2):S30-4.
29. Chresta CM, Davies BR, Hickson I, Harding T, Consulich S, Critchlow SE, et al. AZD8055 is a potent, selective, and orally bioavailable ATP competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70:288-98.